Twist Bioscience Corp. (TWST)
NASDAQHealth CareBiotechnologySnapshot 2026-10-30
$152.78-11.92%
Close 2026-10-30 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-30
Research Workspace
Put TWST beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Life Sciences Tools & Services: structurally weak cohort (structural / late-cycle), so the cyclical early-warning is suppressed.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue is growing steadily — about 19% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 3% on a typical day and fell roughly 35% in its worst 12-month stretch.
View RiskTWST’s DNA synthesis growth must compound through larger customer access, including its Lilly partnership. Revenue grew 23% year over year in Q3 FY2026, but reported GAAP EPS missed consensus. TWST trades at 22× sales versus a 5× peer median, above its 18× historical multiple. Expectations look modest versus our view, despite this substantial peer premium. A 43% modeled next-quarter miss probability adds execution risk. Peer multiples imply a price about 19% below where it trades. This read is provisional.
Trailing returns as of 2026-10-30. TWST is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 13 analysts currently covering TWST (as of Oct 2026).
Based on 9 Wall Street analysts offering 12-month price targets for TWST in the last 4 months.
Continue this research
Compare TWST with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| TWST Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 3 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Life Sciences Tools & Services — fair value, gap to price, and forward P/E.
Compare the value case
Put TWST next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Expand customer base and product shipments
New MRD product expands the portfolio and may support customer adoption and shipments.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $152.78
The last 12 months of price, then the range of analyst 12-month targets from today’s $152.78.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Lilly TuneLab partnership broadens AI drug-discovery exposure and pharma access.
CEO stock sale raises concerns about leadership commitment.
Advances: Expand customer base and product shipments
Eli Lilly partnership expands customer base and product shipments.
Lilly partnership supports AI drug-discovery reach and potential DNA synthesis demand.
Advances: Drive revenue growth with raised FY26 guidance to $456-$457M
Increased demand supports revenue growth objective.
Advances: Drive revenue growth with raised FY26 guidance to $456-$457M
Raised guidance and capital raise materially strengthen growth outlook, though settlement talks add uncertainty.
Advances: Drive revenue growth with raised FY26 guidance to $456-$457M
Reported revenue growth supports execution and technology-led demand.